| P2093 | author name string | Jing Chen | |
| | Linong Ji | |
| | Lingli Zhou | |
| | Qian Ren | |
| | Xueyao Han | |
| | Yingli Chen | |
| | Huaiqing Wang | |
| P2860 | cites work | Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). | Q22241288 |
| | Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man | Q26776977 |
| | Efficacy and safety of traditional chinese medicine for diabetes: a double-blind, randomised, controlled trial | Q28487001 |
| | The Path to Personalized Medicine | Q29541502 |
| | 10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 |
| | Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 |
| | Pharmacologic therapy for type 2 diabetes mellitus | Q33716414 |
| | Standards of medical care in diabetes--2007. | Q34595288 |
| | Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and β-cell function in subjects with long-term remission | Q35123342 |
| | Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program | Q36496759 |
| | Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests | Q36753104 |
| | The unfolded protein response: a pathway that links insulin demand with beta-cell failure and diabetes | Q36861041 |
| | Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients | Q36906186 |
| | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 |
| | Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials | Q37763986 |
| | Individualized treatment of type 2 diabetes mellitus using noninsulin agents: clinical considerations for the primary care physician | Q38036773 |
| | What is the best predictor of future type 2 diabetes? | Q40230327 |
| | Involvement of oxidative stress and the JNK pathway in glucose toxicity | Q42129133 |
| | Pleiotropic Roles of PDX-1 in the Pancreas | Q42280966 |
| | Utilization of oral hypoglycemic agents in a drug-insured U.S. population | Q43687914 |
| | Beta-cell function evaluated by HOMA as a predictor of secondary sulphonylurea failure in Type 2 diabetes | Q43734824 |
| | Secondary sulfonylurea failure: comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide | Q46540130 |
| | Transaminase levels in the upper normal range are associated with oral hypoglycemic drug therapy failure in patients with type 2 diabetes. | Q51158595 |
| | Clinical Predictors of Progressive Beta-Cell Failure in Type 2 Diabetes. | Q51301686 |
| | The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. | Q51500580 |
| | Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastro | Q51576178 |
| P577 | publication date | 2017-02-24 | |
| P1433 | published in | Journal of diabetes | Q27020371 |
| P1476 | title | Factors of primary and secondary sulfonylurea failure in type 2 diabetic subjects | |